Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications. Utilization ...
FDA reviewers argued RECIST v1.1 response and DoR may be inflated because injected-lesion shrinkage could represent local ...
Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential R&D partner for pharma and biotech companies. According to the ...
This episode of The Ron Lanton Report examines why the next phase of healthcare innovation will be constrained not by capital or technology, but by people. Framing the discussion ...
Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...
This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...
A SPAC deal with RA Capital–sponsored RACC is expected to yield ~$175 million gross, including a fully backstopped trust and PIPE/SAFE financing, with closing targeted by end of 2026. Rugonersen, an ...
Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...
Since then, that mindset has continued to grow at AbbVie.
Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...
FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...
Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results